THE INVESTOR

메뉴열기

Metabolic cancer drug developer Haim Bio raises W3b funding

PUBLISHED : December 05, 2017 - 15:29

UPDATED : December 05, 2017 - 15:29

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

[THE INVESTOR] Korean biopharmaceutical firm Haim Bio, which develops a metabolic cancer drug, said on Dec. 5 it has attracted 3 billion won (US$2.75 million) from angel investors.

The company said it plans to complete the phase 1 clinical trials of its next-generation oncology treatment candidate that starves out cancer cells by the first half of 2019. 


7STOCK CEO Song Young-bong (left) and Haim Bio CEO Kim Hong-ryeol.



Haim Bio hopes to commercialize the drug NYH817100 before 2020 by conducting the phase 2 clinical studies for patients with brain, gastric and pancreatic cancer in August 2019.

The investments came as the biotech startup forged a partnership with Korean consulting firm 7STOCK in August to raise funds for the new drug development.

“With the 3 billion won investment, Haim Bio’s oncology drug development will further gather momentum,” 7STOCK CEO Song Young-bong.

This year, Haim Bio acquired the technology involving metabolic targeted therapy of cancer from Korea’s National Cancer Center, following a license-in deal for oncology treatment technology for lung, gastric and brain cancer, co-developed by the center and Yonsei Severance Hospital.

By Park Han-na (hnpark@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
JUVENILE PROTECTION MANAGER : Shin Chang Hoon
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0615|Business info
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.